Versor Investments LP cut its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 43.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,367 shares of the biotechnology company's stock after selling 2,634 shares during the quarter. Versor Investments LP's holdings in Repligen were worth $485,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Blue Trust Inc. lifted its position in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after buying an additional 127 shares during the last quarter. Resources Management Corp CT ADV purchased a new stake in shares of Repligen in the 3rd quarter valued at approximately $37,000. Quarry LP lifted its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares during the period. Finally, Global Retirement Partners LLC boosted its position in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 129 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.
NASDAQ:RGEN traded up $2.72 during trading hours on Friday, hitting $159.26. The company's stock had a trading volume of 453,325 shares, compared to its average volume of 612,083. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $203.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.92 billion, a P/E ratio of -312.27, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The stock has a fifty day moving average of $156.17 and a 200-day moving average of $148.56.
Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, equities analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.
A number of research analysts have commented on the company. TD Cowen started coverage on Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price target on the stock. Royal Bank of Canada raised their target price on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a report on Friday, February 21st. Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $181.00.
Check Out Our Latest Analysis on Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.